Swedish Orphan Biovitrum AB (BIOVF) Financial Statements
Swedish Orphan Biovitrum AB Financial Overview
Swedish Orphan Biovitrum AB's market cap is currently $17.22B. The company's EPS TTM is $19.13; its P/E ratio is 25.62; Swedish Orphan Biovitrum AB is scheduled to report earnings on February 4, 2027, and the estimated EPS forecast is $0.68. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 28.24B | $ 26.03B | $ 22.12B | $ 18.79B | $ 15.53B |
| Gross Profit | $ 12.32B | $ 20.24B | $ 9.95B | $ 13.98B | $ 12.04B |
| Operating Income | $ 8.05B | $ 5.63B | $ 4.07B | $ 3.81B | $ 3.73B |
| EBITDA | $ 10.96B | $ 9.30B | $ 7.23B | $ 6.05B | $ 5.72B |
| Net Income | $ 478.00M | $ 3.88B | $ 2.41B | $ 2.64B | $ 2.68B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 1.04B | $ 1.14B | $ 904.00M | $ 1.36B | $ 1.04B |
| Total Assets | $ 67.43B | $ 75.44B | $ 74.03B | $ 52.50B | $ 48.66B |
| Total Debt | $ 11.49B | $ 16.73B | $ 20.48B | $ 9.10B | $ 10.91B |
| Net Debt | $ 10.45B | $ 15.60B | $ 19.58B | $ 7.74B | $ 9.86B |
| Total Liabilities | $ 29.71B | $ 35.15B | $ 40.16B | $ 25.97B | $ 25.46B |
| Stockholders' Equity | $ 37.72B | $ 40.29B | $ 33.87B | $ 26.52B | $ 23.20B |
| Cash Flow | |||||
| Free Cash Flow | $ 8.52B | $ 4.38B | $ -473.00M | $ 3.10B | $ 5.10B |
| Operating Cash Flow | $ 8.56B | $ 7.39B | $ 4.47B | $ 4.58B | $ 5.47B |
| Investing Cash Flow | $ -4.29B | $ -3.09B | $ -21.90B | $ -1.48B | $ -367.00M |
| Financing Cash Flow | $ -4.32B | $ -4.00B | $ 17.01B | $ -2.90B | $ -4.47B |
Currency in SEK